Lovaza: Clinical Trials

23 trials of Lovaza, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 7 terminated, 7 withdrawn, 1 recruiting. 23 Phase 2, 10 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 223Completed 7, Terminated 7, Withdrawn 7, Recruiting 1, Unknown 1
Phase 110Withdrawn 6, Completed 2, Terminated 2
Phase 32Completed 1, Terminated 1

Follow Lovaza: new trials by email Literature Review of Lovaza trials Research Report on Lovaza

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery
Omega-3 Ethyl Esters 4 g, Omega-3 Ethyl Esters 2 g - Postoperative Delirium
Phase 2TerminatedUniversity of Missouri-Columbia12026-03-032026-05-11
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters - Breast Atypical Hyperplasia, Breast Carcinoma
Phase 2RecruitingNational Cancer Institute (NCI)662025-07-282026-11-19
Immunonutrition for Diabetic Foot Ulcers
Lovaza, L-Arginine Powder, Vitamin C - Diabetes Mellitus, Diabetic Peripheral Neuropathy
Phase 2 / Phase 3TerminatedPrisma Health-Midlands12023-02-082024-12-27
Altering Lipids for Tolerance of Aromatase Inhibitor Therapy
Omega-3 fatty acid supplement - Breast Cancer
Phase 2CompletedUniversity of Michigan Rogel Cancer Center772020-07-282026-05-06
Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)
Omega-3 fatty acid ethyl esters (2 gram) - Colorectal Cancer, Lynch Syndrome
Phase 2UnknownUniversity of Kansas Medical Center212019-02-062023-06-01
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
avelumab, bevacizumab, capecitabine - Colorectal Cancer
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2018-08-012025-02-21
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
avelumab, Bevacizumab, Capecitabine - Non-small Cell Lung Cancer
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2018-02-012025-02-21
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
Aldoxorubicin HCl, ALT-803, ETBX-011 - Pancreatic Cancer
Phase 1 / Phase 2TerminatedImmunityBio, Inc.42017-12-282024-05-22
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
avelumab, bevacizumab, capecitabine - Triple Negative Breast Cancer
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2017-12-012025-02-21
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Avelumab, Bevacizumab, Capecitabine - Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2017-12-012025-02-24
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
avelumab, bevacizumab, capecitabine - Non Hodgkin Lymphoma
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2017-12-012025-02-24
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
avelumab, bevacizumab, capecitabine - Urothelial Carcinoma
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2017-12-012025-02-21
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ALT-803, ETBX-011, GI-4000 - Pancreatic Cancer
Phase 1 / Phase 2TerminatedImmunityBio, Inc.62017-11-062024-12-12
Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury
Omega 3 fatty acid, Safflower seed oil - TBI
Phase 2WithdrawnUniversity of Pennsylvania2017-01-012022-10-13
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention
Eicosapentanoic acid and docosahexanoic acid, Oleic Acid - Colorectal Adenomatous Polyps
Phase 2CompletedVanderbilt University1412013-02-042018-06-08
Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
Lovaza - Hypertriglyceridemia
Phase 1 / Phase 2CompletedSanford Research152009-09-012021-10-20
Fish Oil Study for High Triglyceride Levels in Children
Omega-3-acid ethyl esters, Placebo - Hypertriglyceridemia
Phase 2 / Phase 3CompletedBabu Balagopal422009-07-012022-11-08
Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors
Omega-3 Fatty Acid - Breast Cancer
Phase 2TerminatedColumbia University102009-06-012014-07-23
Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease
Lovaza, Placebo - HIV Infections, Heart Disease
Phase 2CompletedUniversity Hospitals Cleveland Medical Center352009-04-012015-01-07
The Effects of Omega-3 Fatty Acids on Aspirin Resistance
Aspirin, Lovaza, Both Aspirin and Lovaza - Increased Drug Resistance
Phase 1 / Phase 2CompletedUniversity of Rochester272008-11-012012-11-06

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Breast Neoplasms (3)  ·  Colorectal Neoplasms (3)  ·  Hypertriglyceridemia (3)  ·  Cardiovascular Diseases (2)  ·  Pancreatic Neoplasms (2)  ·  Body Weight (1)  ·  Breast Carcinoma In Situ (1)  ·  Carcinoma, Intraductal, Noninfiltrating (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Colorectal Neoplasms, Hereditary Nonpolyposis (1)  ·  Delirium (1)  ·  Diabetes Mellitus (1)  ·  Diabetic Foot (1)  ·  Emergence Delirium (1)

Sponsors

ImmunityBio, Inc. (8)  ·  Babu Balagopal (1)  ·  Boston Children's Hospital (1)  ·  Columbia University (1)  ·  Invitrox (1)  ·  National Cancer Institute (NCI) (1)  ·  Prisma Health-Midlands (1)  ·  Sanford Research (1)  ·  University Hospitals Cleveland Medical Center (1)  ·  University of Illinois at Chicago (1)  ·  University of Kansas Medical Center (1)  ·  University of Michigan Rogel Cancer Center (1)  ·  University of Missouri-Columbia (1)  ·  University of Pennsylvania (1)  ·  University of Rochester (1)

Countries

United States (16)

Top investigators

Anwaar Saeed, MD (1)  ·  Dawn Hershman, MD (1)  ·  Grace McComsey, MD (1)  ·  Gregory C Shearer, PhD (1)  ·  Harvey J Murff, MD, MPH (1)  ·  J. Benjamin Jackson, MD (1)  ·  Lauren Nye (1)  ·  Lynn Henry, MD, PhD (1)  ·  Mauricio Cohen, MD (1)  ·  Quinn Johnson, MD (1)  ·  Ramon Diaz-Arrastia, MD, PhD (1)  ·  Robert C Block, MD, MPH (1)  ·  Samuel Gidding, MD (1)  ·  Sara DeFerranti, MD (1)  ·  Scott Cotler, M.D. (1)

Results publications

PMID 21621252, PMID 21870979, PMID 25393536, PMID 34291724

NIH funding

P30CA046592 (1), R01CA160938 (1), UG1CA242632 (1)